Niagen Bioscience, Inc.
NAGE
$9.88
-$0.16-1.59%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 17.73M | 14.11M | 8.55M | 1.49M | -1.35M |
| Total Depreciation and Amortization | 1.12M | 1.13M | 1.15M | 1.16M | 1.24M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.62M | -1.99M | -722.00K | 4.42M | 5.00M |
| Change in Net Operating Assets | 3.99M | 6.46M | 3.13M | -2.89M | -3.81M |
| Cash from Operations | 21.21M | 19.70M | 12.11M | 4.18M | 1.08M |
| Capital Expenditure | -277.00K | -154.00K | -163.00K | -115.00K | -100.00K |
| Sale of Property, Plant, and Equipment | 20.00K | 20.00K | 20.00K | 20.00K | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -257.00K | -134.00K | -143.00K | -95.00K | -100.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -12.00K | -11.00K | -11.00K | -10.00K | -9.00K |
| Issuance of Common Stock | 11.70M | 8.55M | 5.43M | 1.64M | 598.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -53.00K | -47.00K | -52.00K | -86.00K | -86.00K |
| Cash from Financing | 11.64M | 8.49M | 5.37M | 1.55M | 503.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 32.59M | 28.05M | 17.34M | 5.63M | 1.48M |